Unknown

Dataset Information

0

YTHDF1 Promotes Cyclin B1 Translation through m6A Modulation and Contributes to the Poor Prognosis of Lung Adenocarcinoma with KRAS/TP53 Co-Mutation.


ABSTRACT: KRAS and TP53 mutations are the two most common driver mutations in patients with lung adenocarcinoma (LUAD), and they appear to reduce latency and increase metastatic proclivity when a KRAS and TP53 co-mutation (KRAS/TP53-mut) occurs. However, the molecular mechanism involved is unclear. N6-methyladenosine (m6A), the most abundant RNA modification in mammal mRNAs, plays a critical role in tumorigenesis. Here, we used genomic and transcriptomic data and found that only LUAD patients with KRAS/TP53-mut, but not an individual mutation, appeared to exhibit poor overall survival when compared with patients without KRAS and TP53 mutation (wildtype). Subsequently, we analyzed the differential expression of the 15-m6A-related genes in LUAD with different mutations and found that YTHDF1 was the most upregulated in KRAS/TP53-mut patients and associated with their adverse prognosis. Bioinformatics and experimental evidence indicated that elevated YTHDF1 functionally promoted the translation of cyclin B1 mRNA in an m6A-dependent manner, thereby facilitating the tumor proliferation and poor prognosis of LUAD with KRAS/TP53-mut. Furthermore, the concurrent increase in YTHDF1 and cyclin B1 was confirmed by immunohistochemistry staining in patients with co-occurring KRAS/TP53 mutations. YTHDF1 was correlated with an unfavorable clinical stage and tumor size. Collectively, we identified and confirmed a novel "YTHDF1-m6A-cyclin B1 translation" axis as an essential molecular pathway for the prognosis of KRAS/TP53-mut LUAD.

SUBMITTER: Lou X 

PROVIDER: S-EPMC8305181 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

YTHDF1 Promotes Cyclin B1 Translation through m<sup>6</sup>A Modulation and Contributes to the Poor Prognosis of Lung Adenocarcinoma with KRAS/TP53 Co-Mutation.

Lou Xiaoying X   Ning Jinfeng J   Liu Wei W   Li Kexin K   Qian Benheng B   Xu Danfei D   Wu Yue Y   Zhang Donghong D   Cui Wei W  

Cells 20210702 7


KRAS and TP53 mutations are the two most common driver mutations in patients with lung adenocarcinoma (LUAD), and they appear to reduce latency and increase metastatic proclivity when a KRAS and TP53 co-mutation (KRAS/TP53-mut) occurs. However, the molecular mechanism involved is unclear. <i>N</i><sup>6</sup>-methyladenosine (m<sup>6</sup>A), the most abundant RNA modification in mammal mRNAs, plays a critical role in tumorigenesis. Here, we used genomic and transcriptomic data and found that on  ...[more]

Similar Datasets

| S-EPMC7144925 | biostudies-literature
| S-EPMC8867832 | biostudies-literature
| S-EPMC11372367 | biostudies-literature
| S-EPMC7595883 | biostudies-literature
| S-EPMC11579420 | biostudies-literature
| S-EPMC3787373 | biostudies-literature
| S-EPMC11488328 | biostudies-literature
| S-EPMC7898669 | biostudies-literature
| S-EPMC9682537 | biostudies-literature
| S-EPMC11300455 | biostudies-literature